NDP Slams Federal Government Over Dismissive Pharmacare Response

The federal government’s reaction to a national pharmacare report has been described as “shockingly dismissive” by NDP interim leader Don Davies, who is urging transparency on the program’s future.

Davies, who helped negotiate the Pharmacare Act last year, called the government’s stance politically dishonest. The law, enacted just over a year ago as part of the supply-and-confidence deal between the NDP and Liberals under former Prime Minister Justin Trudeau, mandated the creation of an expert committee to recommend a universal, single-payer pharmacare system.

The committee submitted its findings to Health Minister Marjorie Michel in October, with the report becoming public last month. It recommended that Ottawa fully fund an essential medications list covering over 90% of prescriptions, managed by an independent body, allowing Canadians to access medications at no cost through their health cards.

The report also suggested bypassing prolonged bilateral negotiations with provinces and territories, and called for legislation to enshrine the right to essential medicines in law.

When questioned about implementing the recommendations, Michel said the government is reviewing the report but made no firm commitment to act. “Independent expert panels have their views, but these are non-binding for the government,” she stated. Michel emphasized that her role involves negotiating with provinces and territories, rejecting the idea of unilateral action.

Davies criticized this approach, saying it appears the government rejected the report before studying it. He highlighted that committee members and other stakeholders have been unable to secure a meeting with the health minister since the report’s release.

Committee chair Dr. Nav Persaud stressed that pharmacare is increasingly critical due to international trade pressures, which may impact jobs, insurance coverage, and drug costs. Amy Lamb, another committee member, framed the report as a “nation-building investment” rooted in Canadian principles.

Davies also called on the government to honor the Pharmacare Act by finalizing the first phase, which involves negotiating agreements on contraceptives and select diabetes medications. Only four deals — with B.C., Manitoba, P.E.I., and Yukon — have been signed so far, leaving a patchwork system that health advocates argue is unfair.

“The government continues to present itself as supportive of public access to medications, yet balks when real progress is needed,” Davies said.

Despite campaign promises to protect programs like pharmacare, the government’s first budget under Prime Minister Mark Carney offered no new funding beyond the $1.5 billion earmarked in 2024, much of which is already allocated to existing deals. The committee estimates the cost of funding an essential medications list at $6–10 billion annually but expects net costs of around $3 billion due to savings from competitive purchasing and existing coverage.